Abstract
Proton pump inhibitors (PPIs) are among the most widely used agents in the world. The prevalence of reflux disease is increasing, as is the incidence of oesophageal adenocarcinoma, a complication that is strongly correlated with chronic reflux disease. Although these agents are generally safe, a number of potential side effects have been described and a careful assessment of the risks and benefits of PPI therapy is required in all patients being prescribed long-term therapy.
Overutilization of PPIs is a problem in clinical practice and needs further attention. PPI use has been associated with osteoporosis and bone fracture, hypomagnesaemia, the development of gastric polyps, enteric infections, interstitial nephritis and pneumonia. Patients on long-term therapy should be periodically evaluated for the indications for continued therapy. Despite widespread publicity in the lay press, and regulatory guidance regarding a number of associations, the evidence for serious side effects is poor and the risk of confounding remains a real possibility for many associations. Patients are more concerned about the absolute risk of developing a complication than a relative risk. The absolute risk of all the complications attributed to PPIs is low and patients who need long-term PPI therapy need a clear discussion of the available data on the risk of therapy and also a discussion of the risk of continued reflux.
Similar content being viewed by others
References
Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010 Sep; 16(9): e228–34
Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011 Feb; 11(1): 121–9
IMS. IMS health reports US prescription sales grew 5.1 percent in 2009, to $300.3 billion [media release; online]. Available from URL: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=d690a27e9d5b7210VgnVCM100000ed152ca2RCRD&vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default [Accessed 2011 Oct 1]
El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5(1): 17–26
Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life, and work productivity. Aliment Pharmacol Ther 2007; 25(4): 487–500
Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161(1): 45–52
Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011 Jan; 17(1): 14–27
Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 Mar 18; 340(11): 825–31
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008 Aug 20; 100(16): 1184–7
Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2009 Dec; 7(12): 1299–304
Guda NM, Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol 2004 May; 99(5): 797–800
El-Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006 Aug; 101(8): 1727–33
Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010 Jul; 56(1): 112–6
Cundy T, Dissanayake A. Severe hypomagnesaemia in longterm users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69(2): 338–41
Mackay JD, Bladon PT. Hypomagnesaemia due to protonump inhibitor therapy: a clinical case series. QJM 2010 Jun; 103(6): 387–95
Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6,a new member of the TRPM gene family. Nat Genet 2002; 31: 166–70
Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010 Dec; 25(12): 2786–95
Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010 Oct; 25(10): 2205–11
O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005 Jul; 118(7): 778–81
Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010 Mar; 138(3): 896–904
Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008 Oct; 83(4): 251–9
Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010 May 10; 170(9): 765–71
Targownik LE, Leslie WD. The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 2011 Nov; 10(6): 901–12
Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011 Jul; 106(7): 1209–18
Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011 Apr 1; 48(4): 768–76
Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171(11): 998–1004
Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a populationbased cohort study. Br J Cancer 2009 May 5; 100(9): 1503–7
Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661–9
Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000 May; 46(5): 615–21
Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999 Aug; 117(2): 319–26
Lundell L, Havu N, Miettinen P, et al., Nordic GERD Study Group. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006 Mar 1; 23(5): 639–4
van Soest EM, van Rossum LGM, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966–73
Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case control study. Gastroenterology 2007; 133: 755–60
Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998; 12: 83–98
Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011 Aug; 56(8): 2349–53
Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-heme iron in hereditary hemochromatosis. Gut 2007; 56: 1291–5
Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422–8
den Elzen WPJ, Groeneveld Y, de Ruijter W, et al. Longterm use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491–7
Geevasinga N, Coleman PL, Webster AC, et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006 May; 4(5): 597–604
Vakil N. Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009; 104: S10–6
Laheij RJF, Sturkenboom MCJM, Hassing R-J, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004; 292: 1955–60
Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950–5
Sarkar M, Hennessy S, Yang YX, et al. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391–8
Dublin S, Walker RL, Jackson ML, et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010 Aug; 19(8): 792–802
Yang YX, Metz D. Safety of proton pump exposure. Gastroenterology 2010; 139: 1115–27
Redelmeier DA, McAlister FA, Kandel CE, et al. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ 2010; 340: c2608
Dial S. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104: S10–6
Paredes-Sabja D, Bond C, Carman RJ, et al. Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008; 154: 2241–50
Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007 Sep; 102(9): 2047–56
Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80–7
Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease: is rebound hypersecretion of acid a problem? Scand J Gastroenterol 2011 Apr; 46(4): 398–405
Metz DC, Pilmer BL, Han C, et al. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011 Nov; 106(11): 1953–60
Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses 2011 Sep; 77(3): 451–2
Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007 Jan; 83(975): 66–8
Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010 Nov; 5(4): 288–97
Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005 May 15; 21(10): 1203–9
Pace F, Porro GB. On-demand PPI therapy in GERD. Curr Treat Options Gastroenterol 2008 Feb; 11(1): 35–42
Lobo FS, Wagner S, Gross CR, et al. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2006 Mar; 2(1): 143–51
Acknowledgements
No sources of funding were used to conduct this study or prepare this manuscript. Nimish B. Vakil is a consultant of Astra Zeneca, Takeda, Ironwood; stockholder of Meridian and Orexo; and has received research support from Astra-Zeneca, XenoPort.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vakil, N. Prescribing Proton Pump Inhibitors. Drugs 72, 437–445 (2012). https://doi.org/10.2165/11599320-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11599320-000000000-00000